Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic – Do We Have the Evidence?

1. SARS (Severe Acute Respiratory Syndrome). Available at: https://www.who.int/ith/diseases/sars/en/Search in Google Scholar

2. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia. Available at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/Search in Google Scholar

3. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/Search in Google Scholar

4. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395:1015-1018.10.1016/S0140-6736(20)30673-5Search in Google Scholar

5. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.10.1016/S2213-2600(20)30116-8Search in Google Scholar

6. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781-782.Search in Google Scholar

7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.10.1056/NEJMoa2002032709281932109013Search in Google Scholar

8. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775-1776.10.1001/jama.2020.468332203977Search in Google Scholar

9. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.10.1056/NEJMoa2007621720693132356626Search in Google Scholar

10. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37-55.Search in Google Scholar

11. Richardson S, Hirsch JS, Narasimhan M, el al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052-2059.10.1001/jama.2020.6775717762932320003Search in Google Scholar

12. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201-1228.10.1002/cphy.c130040413791224944035Search in Google Scholar

13. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281-2290.10.1152/ajpheart.00618.2005720356616055515Search in Google Scholar

14. Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. Circulation. 2020. [Epub ahead of print]10.1161/CIRCULATIONAHA.120.04704932213097Search in Google Scholar

15. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.10.1016/j.cell.2020.02.052710262732142651Search in Google Scholar

16. Matsuyama S, Nagata N, Shirato K, Kuwase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658-12660.10.1128/JVI.01542-10300435120926566Search in Google Scholar

17. Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoSOne. 2012;7:e35876.10.1371/journal.pone.0035876334040022558251Search in Google Scholar

18. South, AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16:305-307.10.1038/s41581-020-0279-4711870332246101Search in Google Scholar

19. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-876.10.1038/nm1267709578316007097Search in Google Scholar

20. Ocaranza MP, Godoy I, Jalil JE. Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat. Hypertension. 2006;48:572-578.10.1161/01.HYP.0000237862.94083.4516908757Search in Google Scholar

21. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor-Dependent Mechanism. Hypertension. 2014;64:1368-1375.10.1161/HYPERTENSIONAHA.114.03743423188325225202Search in Google Scholar

22. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.10.1038/nature03712709499816001071Search in Google Scholar

23. Crackower M, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.10.1038/nature0078612075344Search in Google Scholar

24. Huentelman MJ, Grobe JL, Vazquez J. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790.10.1113/expphysiol.2005.03109616049057Search in Google Scholar

25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976.10.1161/01.HYP.0000124667.34652.1a15007027Search in Google Scholar

26. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799-805.10.1097/00004872-199606000-000178793704Search in Google Scholar

27. Arendse LB, Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin–angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019;71:539-570.10.1124/pr.118.017129678202331537750Search in Google Scholar

28. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.10.1074/jbc.M00261520010924499Search in Google Scholar

29. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Resp J. 2008;31:611-617.10.1183/09031936.0016200617959631Search in Google Scholar

30. Christopher H, Manaf Z, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Baylor University Medical Center Proceedings. 2018;31:419-423.10.1080/08998280.2018.1499293641400130948970Search in Google Scholar

31. Yang G, Tan Z, Zhou L, et al. Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension. medRxiv. 2020. [Epub ahead of print]10.1101/2020.03.31.20038935Search in Google Scholar

32. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. EmergMicrob Infect. 2020;9:757-760.10.1080/22221751.2020.1746200717036832228222Search in Google Scholar

33. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;NEJMoa2006923.10.1056/NEJMoa2006923720693332356627Search in Google Scholar

34. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensinaldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;NEJMoa2008975.10.1056/NEJMoa2008975720693232356628Search in Google Scholar

35. Mehta M, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e210855.10.1001/jamacardio.2020.1855720137532936273Search in Google Scholar

36. de Abajo FJ, Rodriguez-Martin S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case population study. Lancet. 2020;395:1705-1714.10.1016/S0140-6736(20)31030-8Search in Google Scholar

37. Khera R, Clark C, Lu Y, et al. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with Coronavirus Disease-19. medRxiv. 2020;20104943.10.1101/2020.05.17.20104943727324932511481Search in Google Scholar

38. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950.10.1001/jamacardio.2020.0950709784132211816Search in Google Scholar

39. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.10.1001/jama.2020.1585704288132031570Search in Google Scholar

40. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 13 Mar 2020. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-onhypertension-on-ace-inhibitors-and-angSearch in Google Scholar

41. American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.Search in Google Scholar